Nontuberculous Mycobacterial Lung Diseases Caused by Mixed Infection with Mycobacterium avium Complex and Mycobacterium abscessus Complex

Mycobacterium avium complex (MAC) and M. abscessus complex (MABC) comprise the two most important human pathogen groups causing nontuberculous mycobacterial lung disease (NTM-LD). However, there are limited data regarding NTM-LD caused by mixed NTM infections. ABSTRACT Mycobacterium avium complex (MAC) and M. abscessus complex (MABC) comprise the two most important human pathogen groups causing nontuberculous mycobacterial lung disease (NTM-LD). However, there are limited data regarding NTM-LD caused by mixed NTM infections. This study aimed to evaluate the clinical characteristics and treatment outcomes in patients with NTM-LD caused by mixed infection with these two major NTM pathogen groups. Seventy-one consecutive patients who had been diagnosed with NTM-LD caused by mixed infection with MAC (M. avium or M. intracellulare) and MABC (M. abscessus or M. massiliense) between January 2010 and December 2015 were identified. Nearly all patients (96%) had the nodular bronchiectatic form of NTM-LD. Mixed infection with MAC and M. massiliense (n = 47, 66%) was more common than mixed infection with MAC and M. abscessus (n = 24, 34%), and among the 43 (61%) patients who were treated for NTM-LD for more than 12 months, sputum culture conversion rates were significantly lower in patients infected with MAC and M. abscessus (25% [3/12]) than in patients infected with MAC and M. massiliense (61% [19/31, P = 0.033]). Additionally, M. massiliense and M. abscessus showed marked differences in clarithromycin susceptibility (90% versus 6%, P < 0.001). Of the 23 patients who successfully completed treatment, 11 (48%) redeveloped NTM lung disease, with mycobacterial genotyping results indicating that the majority of cases were due to reinfection. Precise identification of etiologic NTM organisms could help predict treatment outcomes in patients with NTM-LD due to mixed infections.

[1]  O. Kwon,et al.  Amikacin Inhalation as Salvage Therapy for Refractory Nontuberculous Mycobacterial Lung Disease , 2018, Antimicrobial Agents and Chemotherapy.

[2]  S. Holland,et al.  Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement , 2018, European Respiratory Journal.

[3]  Jong Hyuk Lee,et al.  Implication of species change of Nontuberculous Mycobacteria during or after treatment , 2017, BMC Pulmonary Medicine.

[4]  C. Ki,et al.  Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype , 2017, European Respiratory Journal.

[5]  S. Madhi,et al.  Safety of Induced Sputum Collection in Children Hospitalized With Severe or Very Severe Pneumonia , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  K. Rabe,et al.  Burden of non-tuberculous mycobacterial pulmonary disease in Germany , 2017, European Respiratory Journal.

[7]  S. Shin,et al.  Clofazimine-Containing Regimen for the Treatment of Mycobacterium abscessus Lung Disease , 2017, Antimicrobial Agents and Chemotherapy.

[8]  J. Yim,et al.  Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  Yong Soo Choi,et al.  Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  L. Wymer,et al.  Increasing Prevalence Rate of Nontuberculous Mycobacteria Infections in Five States, 2008-2013. , 2016, Annals of the American Thoracic Society.

[11]  D. Griffith,et al.  Nontuberculous Mycobacterial Disease Therapy: Take It to the Limit One More Time. , 2016, Chest.

[12]  Chang Ki Kim,et al.  Oral Macrolide Therapy Following Short-term Combination Antibiotic Treatment of Mycobacterium massiliense Lung Disease. , 2016, Chest.

[13]  C. Qi,et al.  Relapse versus Reinfection of Mycobacterium avium Complex Pulmonary Disease. Patient Characteristics and Macrolide Susceptibility. , 2016, Annals of the American Thoracic Society.

[14]  T. Ishida,et al.  18 Cases of pulmonary Mycobacterium abscessus: Clinical difference depending on the presence or absence of Mycobacterium avium complex. , 2016, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[15]  S. Field,et al.  Long-term Follow-up of Mycobacterium avium Complex Lung Disease in Patients Treated With Regimens Including Clofazimine and/or Rifampin. , 2016, Chest.

[16]  J. Stout,et al.  Update on pulmonary disease due to non-tuberculous mycobacteria. , 2016, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[17]  R. Wilson,et al.  The antimicrobial susceptibility of non-tuberculous mycobacteria. , 2016, The Journal of infection.

[18]  Jae Ho Lee,et al.  Determinants of recurrence after successful treatment of Mycobacterium avium complex lung disease. , 2015, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[19]  R. Wallace,,et al.  The significance of Mycobacterium abscessus subspecies abscessus isolation during Mycobacterium avium complex lung disease therapy. , 2015, Chest.

[20]  T. Shim,et al.  Risk Factors for Recurrence after Successful Treatment of Mycobacterium avium Complex Lung Disease , 2015, Antimicrobial Agents and Chemotherapy.

[21]  E. Chan,et al.  Pathogenesis and risk factors for nontuberculous mycobacterial lung disease. , 2015, Clinics in chest medicine.

[22]  J. Falkinham.  Environmental sources of nontuberculous mycobacteria. , 2015, Clinics in chest medicine.

[23]  J. Philley,et al.  Treatment of slowly growing mycobacteria. , 2015, Clinics in chest medicine.

[24]  T. Shim,et al.  A shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease. , 2014, Respiratory medicine.

[25]  J. Stout,et al.  Advances in the management of pulmonary disease due to Mycobacterium abscessus complex. , 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[26]  R. Wallace,,et al.  Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. , 2014, Chest.

[27]  J. Shelhamer,et al.  Abnormal nasal nitric oxide production, ciliary beat frequency, and Toll-like receptor response in pulmonary nontuberculous mycobacterial disease epithelium. , 2013, American journal of respiratory and critical care medicine.

[28]  Chang Ki Kim,et al.  Treatment of Refractory Mycobacterium avium Complex Lung Disease with a Moxifloxacin-Containing Regimen , 2013, Antimicrobial Agents and Chemotherapy.

[29]  G. Fantuzzi,et al.  Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes. , 2013, American journal of respiratory and critical care medicine.

[30]  E. Chan,et al.  Underlying Host Risk Factors for Nontuberculous Mycobacterial Lung Disease , 2013, Seminars in Respiratory and Critical Care Medicine.

[31]  K. Lee,et al.  Clinical significance of the differentiation between Mycobacterium avium and Mycobacterium intracellulare in M avium complex lung disease. , 2012, Chest.

[32]  S. Shin,et al.  Successful Treatment of Mycobacterium massiliense Lung Disease with Oral Antibiotics Only , 2012, Antimicrobial Agents and Chemotherapy.

[33]  T. Iwamoto,et al.  Clinical and Microbiological Differences between Mycobacterium abscessus and Mycobacterium massiliense Lung Diseases , 2012, Journal of Clinical Microbiology.

[34]  John D. Mitchell,et al.  Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  R. Wallace,,et al.  Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes , 2011 .

[36]  Young Kil Park,et al.  Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. , 2011, American journal of respiratory and critical care medicine.

[37]  N. Ampel.  Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases , 2007 .

[38]  D. Lynch,et al.  Nontuberculous mycobacterial infection: CT scan findings, genotype, and treatment responsiveness. , 2005, Chest.

[39]  D. Lynch,et al.  Nontuberculous Mycobacterial Infection: CT Scan Findings, Genotype, and Treatment Responsiveness , 2005 .

[40]  J. Lupski,et al.  Microbial DNA Typing by Automated Repetitive-Sequence-Based PCR , 2005, Journal of Clinical Microbiology.

[41]  R. Wallace,,et al.  Polyclonal Mycobacterium avium complex infections in patients with nodular bronchiectasis. , 1998, American journal of respiratory and critical care medicine.

[42]  R. Wallace,,et al.  Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. , 1993, The American review of respiratory disease.

[43]  Lloyd N. Friedman,et al.  Diagnostic standards and classification of tuberculosis. , 1991, The American review of respiratory disease.

[44]  H. Namkoong,et al.  A Laboratory‐based Analysis of Nontuberculous Mycobacterial Lung Disease in Japan from 2012 to 2013 , 2017, Annals of the American Thoracic Society.

[45]  D. Griffith.  Clinical features of disease caused by rapidly growing mycobacteria , 1993 .